ORIGINAL
RESEARCH

H. Vrenken
A. Seewann
D.L. Knol
C.H. Polman
F. Barkhof
J.J.G. Geurts

Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types

BACKGROUND AND PURPOSE: Recent postmortem studies in MS brain suggest that the severity of changes in DAWM can be measured by using quantitative MR imaging. This study aimed to characterize DAWM in vivo by using 4 quantitative MR imaging measures and to explore differences between MS disease types.

MATERIALS AND METHODS: In 17 patients with chronic MS (7 PP, 10 SP), quantitative MR imaging was performed at 1.5T, yielding whole-brain voxelwise maps of T1, MTR, ADC, and FA. ROIs were placed to obtain values for DAWM, NAWM, and WM lesions. A general linear mixed-model analysis was used to compare T1, MTR, ADC, and FA between tissue types and disease types.

RESULTS: Values of T1, MTR, ADC, and FA for DAWM were intermediate to those observed in NAWM and WM lesions. In patients with SPMS, DAWM was significantly different from both WM lesions and NAWM regarding all 4 measures, while in patients with PPMS, DAWM differed significantly from NAWM regarding T1, MTR, and FA and from lesions only regarding FA. Most interesting, DAWM differed between disease types: DAWM in patients with SPMS exhibited significantly higher T1 and lower MTR than did DAWM in patients with PPMS.

CONCLUSIONS: In vivo T1, MTR, ADC, and FA reflect the variable severity of pathologic changes in DAWM in MS. Moreover, these quantitative MR imaging measures suggest that DAWM may differ between PPMS and SPMS.

ABBREVIATIONS: ADC = apparent diffusion coefficient; DAWM = diffusely abnormal white matter; EDSS = Expanded Disability Status Scale; FA = fractional anisotropy; FLASH = fast low-angle shot; IQR = interquartile range; kfor = forward magnetization exchange rate; MS = multiple sclerosis; MTR = magnetization transfer ratio; NAWM = normal-appearing white matter; Pd = proton density; PP = primary progressive; PPMS = primary progressive multiple sclerosis; ROI = region of interest; SP = secondary progressive; SPMS = secondary progressive multiple sclerosis; STEAM = stimulated echo acquisition mode; T1 = T1 relaxation time; T1free = native T1 relaxation time; WM = white matter

In the brain of patients with MS, in vivo MR imaging often shows fuzzy-bordered areas of subtly increased signal intensity on Pd or T2-weighted images. These abnormalities have been referred to as dirty WM, dirty-appearing WM, or DAWM.¹⁻⁴ The use of varying criteria renders comparisons among these studies difficult. A previous article has proposed a set of MR imaging criteria to define DAWM, applied them in

a postmortem setting, and concluded that the use of these specific criteria yields only areas with truly diffuse pathology, without including multifocal lesional pathology.⁴

Recently, these areas of DAWM have been characterized histopathologically and were found to contain tissue changes indicating a chronic pathology, including axonal loss, myelin loss, and chronic isomorphic gliosis.^{4,5} However, the severity of these changes may vary among patients. On the basis of previous histopathology and MR imaging results, DAWM is believed to represent a separate pathologic entity in MS,^{4,5} in addition to MR imaging-visible focal WM lesions, focal lesions in the gray matter, and subtle changes in the so-called normal-appearing brain tissue. Because DAWM pathology appears to be chronic, most likely reflecting secondary axonal degeneration, one could hypothesize that monitoring DAWM in vivo may give important information on the progression of the disease. In any case, the histopathologic changes observed in DAWM suggest that to obtain a full in vivo assessment of the total disease burden, the tissue damage in DAWM should be taken into account.

Beyond the mere detection of DAWM areas on T2-weighted images, measures are required that can reflect the severity of the pathology in DAWM regions because this se-

Received May 5, 2009; accepted after revision July 2.

From the Departments of Radiology (H.V., J.J.G.G.), Physics and Medical Technology (H.V.), Neurology (A.S., C.H.P.), Epidemiology and Biostatistics (D.L.K., F.B.), and Pathology (J.J.G.G.), MS Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.

The MS Center Amsterdam is supported by the Dutch MS Research Foundation through a program grant (05-358c). This study was further supported by the Dutch MS Research Foundation through a project grant (98-371). A.S. was supported by the Dutch MS Research Foundation through a pilot project grant (08-633 MS).

Paper previously presented at: Pathogenesis and Mechanisms of White Matter Injury workshop organized by the International Society for Magnetic Resonance in Medicine White Matter Study Group, Krakow, Poland, September, 23-26, 2008.

Please address correspondence to H. Vrenken, MD, Departments of Radiology and Physics and Medical Technology, VU University Medical Center, De Boelelaan 1118, 1081 HV Amsterdam, the Netherlands; e-mail: H.Vrenken@vumc.nl

Indicates open access to non-subscribers at www.ajnr.org

DOI 10.3174/ajnr.A1839

verity appears to be variable. Using quantitative MR imaging, Seewann et al⁴ demonstrated that in the postmortem setting, quantitative MR imaging measures reflect the degree of tissue change as measured by histopathologic methods. These quantitative MR imaging measures are, therefore, important candidates for quantifying the DAWM disease burden in patients in vivo.

To date, few studies have investigated diffuse WM changes by using quantitative MR imaging techniques in an in vivo setting. In 2 studies, both with small numbers of patients and ROIs, values for MTR, k_{for}, and T1_{free} of diffuse WM changes were intermediate to those of NAWM and focal WM lesions,^{3,6} and 1 of these observed lower k_{for} and higher T1_{free} in diffuse abnormalities compared with those in NAWM.⁶ A larger histogram-based study found that MTR values distinguished diffuse changes from NAWM and focal WM lesions.² Finally, in a study of 13 patients, T2 relaxation times of diffuse changes were higher than those of NAWM and lower than those of focal WM lesions.⁷ The varying criteria used to define diffuse abnormalities in these studies, specifically regarding whether multifocal lesions were included, make it difficult to draw reliable conclusions about the nature of the areas of truly diffuse pathology. Furthermore, no comparisons between MS disease types have been reported.

The present study aimed to characterize and quantify changes in purely diffuse DAWM in vivo in progressive MS, defined following previously proposed MR imaging criteria,⁴ by using quantitative MR imaging techniques. This study investigated the progressive disease types because DAWM seems to be more prevalent in progressive MS than in relapsing-remitting MS (Seewann et al, unpublished general observations). Second, we aimed to investigate whether differences in the severity of DAWM pathology exist between PP and SPMS.

Materials and Methods

Patients

Data previously acquired as part of an academic quantitative MR imaging study were retrospectively selected, including only patients with progressive MS who had results for all 3 techniques: diffusion tensor imaging, MTR, and T1, yielding a subgroup of the total group of progressive patients originally studied.⁸⁻¹⁰

Quantitative MR Imaging Techniques

This section briefly describes the 3 quantitative MR imaging techniques used in this study. T1 mapping produces voxelwise maps of the longitudinal relaxation time, T1, assuming monoexponential decay. In MS, T1 has been shown to be increased in different pathologic processes, most prominently axonal damage but also edema, demyelination, and gliosis.^{4,11-16} MTR mapping produces voxelwise maps of the relative amount of signal-intensity decrease that results from adding a magnetization-preparation prepulse to a pulse sequence. The MTR is a semiquantitative measure that is ultimately determined by more fundamental parameters such as the fraction of bound pool protons, the magnetization exchange rate between bound and free protons, and the relaxation rates. As such, MTR can theoretically be expected to be altered especially by demyelination and edema, though it has been suggested that inflammation per se may also decrease MTR.¹⁷ Correlative imaging—histopathologic studies in MS have found reduced MTR to be associated with a lower grade of myelina-

tion^{4,18,19}; similar relations of MTR with axonal loss are thought to result from the close relation between demyelination and axonal loss.¹⁷

Finally, diffusion tensor imaging uses magnetic field gradients to sensitize the MR imaging signal intensity to the effects of water diffusion in several directions; and from the results of these multiple measurements, the water self-diffusion tensor is calculated. Two important parameters that can be deduced from this tensor are the ADC, which can be interpreted as reflecting the overall magnitude of diffusion, and the FA, which reflects the degree to which the diffusion has a preferential direction. Diffusion tensor imaging was used in this study to create voxelwise maps of both ADC and FA. Increased ADC and decreased FA in MS have both been associated with a lower grade of myelination and with axonal loss, and it has been suggested that the relation with axonal loss is largely determined by its relation to demyelination.^{4,20}

MR Image Acquisition

MR imaging investigations were performed on a 1.5T Magnetom Vision MR imaging system (Siemens, Erlangen, Germany) with the standard circularly polarized head coil. A fast spin-echo technique was used to generate Pd and T2-weighted images (TR, 2625 ms; TE, 16/98 ms) for 2 interleaved sets of 16 sections covering the whole brain (section thickness, 4 mm; in-plane resolution, 1 × 1 mm²).

For T1 mapping,²¹ six 3D FLASH image sets were acquired (TR/TE, 20/4 ms; NEX, 1; bandwidth, 244 Hz/pixel), with nominal flip angles of 2°, 5°, 10°, 15°, 20°, and 25° (small flip angle array), by using a 128-mm 3D slab consisting of thirty-two 4-mm sections, with the same position, orientation, and resolution as the Pd/T2-weighted images. Acquisition took approximately 8 minutes.

For MTR mapping, 2 sets of 3D FLASH images covering the same volume were acquired (TR/TE, 27/4 ms; flip angle, 20°; NEX, 2; 1 × 1 × 4 mm³ voxels), 1 with a magnetization transfer prepulse (gaussian pulse shape, 7.68-ms duration; frequency offset, 1500 Hz; equivalent flip angle, 500°), and 1 without. Acquisition took approximately 5 minutes.

For B₁ correction of the T1 and MTR measurements, sagittal 3D FLASH images (TR/TE, 25/5 ms; NEX, 1; bandwidth, 244 Hz/pixel; 200-mm 3D slab; 2 × 2 × 4 mm³ voxels) were acquired with nominal flip angles of 140°, 160°, 180°, 200°, and 220° (large flip angle array). Acquisition took approximately 12 minutes.

Diffusion tensor mapping was performed for 20 contiguous 6-mm sections with 2 × 2 mm² pixels, again with the same orientation and in-plane FOV as the T2-weighted images, by using a diffusion-weighted single-shot short TE STEAM sequence,²² with gradients in 6 noncollinear directions; b-value, 750 s/mm²; flip angle, 11°; effective TE, 65 ms; and 4 acquisitions. Acquisition took approximately 6 minutes.

MR Image Analysis

Calculation of Supratentorial Lesion Volume. To calculate supratentorial lesion loads, we manually marked MR imaging—visible abnormalities and semiautomatically outlined them on the Pd-weighted images by using in-house-developed software (Show_Images, VU University Medical Center, Amsterdam, the Netherlands), using a seed-growing technique with a local threshold.

Quantitative MR Imaging Analysis

T1 Mapping. Whole-brain T1 maps (Fig 1) were obtained as previously described.⁹ Briefly, the small flip angle array images were

Fig 1. Sample of maps of quantitative MR imaging measures for 1 axial section in a female patient with PPMS (59.5 years of age; disease duration, 8.3 years; EDSS score, 4.0; total focal WM lesion volume on T2, 14.9 mL). Images show maps of the T1 (A), MTR (B), ADC (C), and FA (D). The empty (black) voxels located centrally in the maps of T1 and MTR are voxels excluded from analyses because of insufficient accuracy in determining the local effective B_1 field strength in and close to the CSF. Details of methods are provided in the text.

Fig 2. Early-echo (Pd) images from a T2-weighted 2D dual-echo fast spin-echo sequence used to identify and outline focal WM lesions, DAWM, and NAWM. Images shown are from a male patient with SPMS (45.7 years of age; disease duration, 11.1 years; EDSS score, 4.0; total focal WM lesion volume on T2, 21.9 mL). The top row shows the images of 5 consecutive sections used for placing ROIs in this patient. The bottom row shows the same images but with the ROIs overlaid. The ROIs placed in each section are left frontal focal WM lesion (blue), left frontal DAWM (green) (A); right parieto-occipital DAWM (blue) (B); right frontal DAWM (red) (C); right frontal focal WM lesion (green), right parieto-occipital focal WM lesion (yellow), left parieto-occipital focal WM lesion (pink), and left parieto-occipital DAWM (yellow) (D); and right frontal NAWM (blue), left frontal NAWM (green), right parieto-occipital NAWM (pink), and left parieto-occipital NAWM (yellow) (E).

coregistered with FLIRT (FMRIB's linear image registration tool)^{23,24}; T1 was then calculated²¹ for each pixel by nonlinear least-squares fitting by using a hill-climbing algorithm, correcting the flip angle values for the local effective B_1 field strength, which was calculated from the signal-intensity zero crossing²¹ in the large flip angle array images.

MTR Mapping. Whole-brain MTR maps were obtained as previously described.¹⁰ Briefly, 3D FLASH images acquired with and without magnetization transfer prepulse were coregistered, MTR maps were generated, and a correction for B_1 -induced variation was applied for each subject by using the method described by Ropele et al.²⁵

ADC and FA Mapping. ADC and FA maps were generated as previously described.⁸ Briefly, maps of the 6 unique diffusion tensor elements were calculated from the raw data and then used to calculate ADC and FA maps.²⁶

ROI for Quantitative MR Imaging Analysis

Figures 2 and 3 illustrate how the ROIs were placed in the different tissue types. In this study, DAWM was defined as a uniform nonfocal area of signal increase on the Pd-weighted sequence, in which the signal increase is more subtle than the signal increase of focal WM lesions. ROIs were placed by manual outlining on the Pd-weighted images. To avoid regional bias, we aimed to sample all 3 tissue types (NAWM, DAWM, and focal WM lesions) in 4 locations: left and right frontal WM and left and right parieto-occipital WM, leading to a total of 12 ROIs per patient. Another interesting region, the periventricular region, unfortunately had to be discarded because images of too many patients did not exhibit NAWM in that region, which would have led to systematic bias in the sampling. If a tissue type was not present in a particular location, the corresponding ROI was not placed. To provide good sampling of NAWM, we used ROIs in NAWM that were

Table 1: Demographic and clinical characteristics^a

	PPMS	SPMS	<i>P</i> Value for Comparison: PPMS vs SPMS
No. of patients	7	10	
Sex: M/F	3/4	3/7	.6
Age (yr) (mean ± SD)	59.2 ± 5.9	43.8 ± 10.3	.002
Disease duration (yr): Median (IQR)	8.3 (3.8–16.4)	15.9 (8.7–23.7)	.3
EDSS score: median (IQR)	4.5 (3.0–4.5)	5.5 (4.0–6.75)	.2
Supratentorial focal WM lesion volume (mL): median (IQR)	3.6 (1.4–13.8)	15.5 (3.9–23.6)	.07

^a *P* values for the comparison between patients with PPMS and SPMS are derived from the Mann-Whitney *U* test, except for sex, for which Pearson χ^2 was used.

Table 2: Median number (volume) of analyzed voxels per patient in each tissue type for each quantitative MR imaging measure^a

Tissue Type	Technique			
	ADC/FA	MTR	T1	Pd
NAWM	117.5 (2.8 mL)	624 (2.5 mL)	660 (2.6 mL)	660 (2.6 mL)
DAWM	53 (1.3 mL)	327 (1.3 mL)	283 (1.1 mL)	200 (0.8 mL)
Focal WM lesions	19.5 (0.5 mL)	117 (0.5 mL)	123.5 (0.5 mL)	80.5 (0.3 mL)

^a Median values are given for the entire group of patients in this study. A more detailed subdivision by anatomic region and disease type is provided in Table 3. The size of each region of interest was defined as the total number of voxels included in the ROI, after warping it to the corresponding quantitative MR imaging maps as described in the text. The corresponding ROI volume was calculated by multiplying the number of voxels by the appropriate voxel volume, which was 4 mm³ for the T1 and MTR maps, and 24 mm³ for the ADC and FA maps. The column headed "Pd" gives the values for the original ROIs as drawn on the Pd-weighted images.

fairly large compared with those in DAWM and lesions, in which the sizes of the pathologic areas present in the 4 anatomic regions studied here created limitations on the size of ROIs that could be drawn, especially sometimes leading to small ROIs in lesions. Within these limitations, we aimed to draw ROIs of roughly similar size in DAWM and lesions. For each tissue type, we attempted to draw similar-sized ROIs in the different anatomic regions as much as possible.

Within each patient, ROIs were then combined for each tissue type, giving 1 combined ROI for DAWM, 1 for NAWM, and 1 for focal WM lesions. Using FLIRT,^{23,24} we registered the patient's T2-weighted images to their MTR, T1, and ADC/FA maps, by using the corresponding native images as a reference. The transformation matrices thus obtained were applied to the binary ROIs, by using trilinear interpolation and a 25% intensity threshold, yielding binary ROIs in the MTR, T1, ADC, and FA map spaces, which were used to calculate the average MTR, T1, ADC, and FA for each tissue type for that patient.

Statistical Analysis

Clinical variables and supratentorial lesion volumes were compared between patients with PPMS and SPMS by using the Mann-Whitney *U* test, except for sex for which the Pearson χ^2 test was used.

For each quantitative MR imaging parameter (MTR, T1, ADC, FA), a model was constructed incorporating all 3 tissue types and all patients. A general linear mixed model was used with the tissue types nested within patients and an unstructured covariance matrix. The model further contained disease type (PPMS or SPMS) and the interaction between disease type and tissue type. If the interaction between disease type and tissue type was not significant at the *P* = .05 level, differences between PPMS and SPMS and pair-wise differences among the 3 tissue types were assessed by using post hoc Bonferroni-adjusted contrasts. If there was a significant interaction between disease type and tissue type, post hoc Bonferroni-adjusted contrasts were set up to assess differences between PPMS and SPMS within each of the 3 tissue types separately and, similarly, to assess differences among the 3 tissue types within patients with PPMS and SPMS separately. *P* values below .05 were considered statistically significant.

Results

Patients

Demographic and clinical characteristics are given in Table 1. Sex distributions in both groups were as expected, with relatively more women in the SPMS group, but this difference was not significant (*P* = .6). Disease durations were shorter in the PPMS group (*P* = .3), while patients with PPMS were significantly older than those with SPMS (*P* = .002), as expected from the higher average age at onset of PPMS. EDSS scores were higher in the SPMS group (*P* = .2). The T2 focal WM lesion volumes were higher in the SPMS group compared with the PPMS group (*P* = .07).

ROIs

A total of 190 ROIs were placed in the 17 patients included in this study, with 12 ROIs per patient except in the following cases: In 2 patients, no parieto-occipital lesions were found. In another patient, no parieto-occipital DAWM was found. In 1 patient with PPMS, no lesion was found in the frontal or parieto-occipital WM, so no lesion ROI could be placed. Similarly, in 1 patient with SPMS, no NAWM ROI could be placed. The numbers of patients analyzed in each tissue category were therefore the following: DAWM: 7 PP, 10 SP; focal WM lesions: 6 PP, 10 SP; NAWM: 7 PP, 9 SP. Table 2 lists the median numbers and volumes of analyzed voxels for each quantitative MR imaging measure in each tissue type, as well as the same number for the original ROIs drawn on the Pd-weighted images. Table 3 provides more detail on the ROIs as drawn on the Pd-weighted images, listing the median numbers and IQRs for each patient group by anatomic region and tissue type. As indicated in "Materials and Methods," NAWM ROIs were larger than those for DAWM or lesions. Also, DAWM ROIs were larger than lesion ROIs. The largest discrepancies between the PPMS and SPMS groups were seen for parieto-occipital DAWM and parieto-occipital lesions.

Table 3: Number of voxels (medians and IQRs) in the ROI drawn on the Pd-weighted images^a

Disease Type, Region	NAWM		DAWM		Lesions	
	Median	IQR	Median	IQR	Median	IQR
PPMS						
Frontal	314.0	247.5–338.5	89.0	79.5–120.0	25.0	17.0–56.0
Parieto-occipital	318.0	305.0–379.5	128.0	111.0–156.0	32.0	26.0–52.0
Combined	593.0	528.0–713.0	212.0	190.5–265.5	57.0	17.0–80.0
SPMS						
Frontal	394.0	238.0–452.0	99.0	69.0–121.0	40.5	32.0–87.0
Parieto-occipital	390.0	319.0–501.0	94.5	76.0–114.0	56.0	36.0–61.0
Combined	703.0	629.0–921.0	193.0	141.0–238.0	95.0	71.0–144.0

^a The “Combined” ROI for each patient is the combination of the frontal and parieto-occipital ROIs for that tissue type (NAWM, DAWM, or lesions).

Table 4: Quantitative MR imaging parameters by tissue type and clinical group^a

		NAWM	DAWM	Lesions	Significant Pair-wise Comparisons between Tissue Types	Significant Comparisons between Disease Types
ADC ($\mu\text{m}^2 \text{s}^{-1}$)	PP	805 $\pm$ 53	842 $\pm$ 48	1042 $\pm$ 216	Lesions vs NAWM, $P < .05$	–
	SP	798 $\pm$ 40	903 $\pm$ 77	1201 $\pm$ 131	DAWM vs NAWM, $P < .001$; DAWM vs lesions, $P < .001$; lesions vs NAWM, $P < .001$	
FA	PP	0.383 $\pm$ 0.058	0.350 $\pm$ 0.047	0.318 $\pm$ 0.110	DAWM vs NAWM $P < .01$; DAWM vs lesions, $P < .05$; lesions vs NAWM, $P < .001$	–
	SP	0.365 $\pm$ 0.033	0.322 $\pm$ 0.030	0.242 $\pm$ 0.054	DAWM vs NAWM, $P < .001$; DAWM vs lesions, $P < .001$; lesions vs NAWM, $P < .001$	
MTR (%)	PP	32.9 $\pm$ 0.6	31.1 $\pm$ 1.0	28.2 $\pm$ 3.6	DAWM vs NAWM, $P < .01$; lesions vs NAWM, $P < .05$	DAWM SP vs PP, $P < .001$; lesions SP vs PP, $P < .01$
	SP	32.8 $\pm$ 1.2	28.8 $\pm$ 0.8	21.3 $\pm$ 3.3	DAWM vs NAWM, $P < .001$; DAWM vs lesions, $P < .001$; lesions vs NAWM, $P < .001$	
T1 (ms)	PP	759 $\pm$ 27	823 $\pm$ 38	1040 $\pm$ 185	DAWM vs NAWM, $P < .05$	DAWM SP vs PP, $P < .001$;
	SP	815 $\pm$ 47	958 $\pm$ 67	1419 $\pm$ 298	DAWM vs NAWM, $P < .001$; DAWM vs lesions, $P < .001$; lesions vs NAWM, $P < .001$	lesions SP vs PP, $P < .05$

^a Means and SDs of ADC, FA, MTR, and T1 in NAWM, DAWM, and lesions by clinical group (PP or SPMS). Bonferroni-corrected P values derived from general linear mixed model analysis are indicated for statistically significant pair-wise differences between tissue types and disease types. Details of statistical analyses are provided in the text.

Fig 3. Further illustration of the radiologic definition of DAWM and placement of ROIs. Images shown are from a male patient with PPMS (52.3 years of age; disease duration, 2.3 years; EDSS score, 3.0; total focal WM lesion volume on T2, 6.9 mL). The left part of the figure shows the early-echo (Pd) image of 1 section from the T2-weighted 2D dual-echo fast spin-echo sequence. Images are in radiologic convention: The right side of the body is on the left side of the image. The right part of the figure shows the same image but with the parieto-occipital DAWM ROIs used in this study as a color overlay. The right parieto-occipital DAWM ROI is shown in light blue; the left parieto-occipital DAWM ROI is shown in yellow.

Quantitative MR Imaging Characterization of DAWM

Table 4 and Fig 4 show the observed values of the quantitative MR imaging measures. Values observed in DAWM were intermediate to those observed in focal WM lesions and those

observed in NAWM. For ADC, MTR, and T1, the interaction between disease type and tissue type was significant, whereas for FA, the interaction between disease type and tissue type was not significant; in both cases, the appropriate method was used to assess pair-wise contrasts.

In patients with SPMS, the discrimination among tissue types was clearest: DAWM differed significantly from both focal WM lesions and NAWM regarding all 4 quantitative MR imaging measures. ADC and T1 were significantly higher (by between 10% and 20%) in DAWM than in NAWM and significantly lower than in focal WM lesions (by approximately 25%). FA and MTR were significantly lower in DAWM compared with NAWM (by approximately 10%) and significantly higher compared with lesions (by approximately 30%).

In patients with PPMS, DAWM differed significantly from NAWM, in that FA and MTR were significantly lower in DAWM (by between 5% and 10%) and T1 was significantly higher in DAWM (by approximately 10%), whereas DAWM differed significantly from focal WM lesions only regarding FA, which was approximately 10% higher in DAWM compared with focal WM lesions.

Focal WM lesions and NAWM were significantly different regarding all 4 quantitative MR imaging measures and in both disease types (Table 3, Fig 4), with the exception of T1 in

Fig 4. Boxplots showing median, range, and 25th and 75th percentiles for T1 (A), MTR (B), ADC (C), and FA (D). Each boxplot shows data split according to patient group (either PP or SPMS) as well as according to tissue type (NAWM, DAWM, or focal WM lesions). The plots clearly demonstrate that the values for the quantitative MR imaging measures observed in DAWM are intermediate to those observed in NAWM and focal WM lesions.

PPMS, which did not significantly differ between NAWM and focal WM lesions.

Comparison between PPMS and SPMS

DAWM differed between PPMS and SPMS regarding MTR and T1, with MTR lower and T1 higher in SPMS DAWM compared with PPMS DAWM, both associated with more severe MS-related tissue changes. No differences were observed between PPMS and SPMS regarding ADC or FA of DAWM. Similarly, focal WM lesions had lower MTR and higher T1 in SPMS compared with PPMS, again suggesting more severe

damage in the patients with SPMS, while lesional ADC and FA did not differ between SPMS and PPMS.

Discussion

This study demonstrates that 4 in vivo quantitative MR imaging measures enable a clear discrimination between DAWM and other tissue pathologies in MS brain and that T1 and MTR may differentiate between DAWM in PPMS and SPMS.

The ability of quantitative MR imaging to reflect histopathologic changes in DAWM has recently been demonstrated in postmortem tissue.^{4,5} In the in vivo imaging setting

used in the present study, no distinction can be made between truly diffuse pathology and areas containing multiple microscopic lesions. Therefore, DAWM was selected on the basis of well-defined MR imaging criteria that have been shown in postmortem imaging to lead to inclusion of truly diffuse abnormalities, without including multifocal lesional pathology. Hence, this study is the first to give real in vivo insight in the pathology of “pure” diffusely abnormal WM, by using a pathologically confirmed method to select it. The results are in agreement with the limited data available from previous in vivo quantitative MR imaging studies, in which MTR,^{2,3} kfor,^{3,6} T1free,^{3,6} and T2⁷ were measured in “diffuse” WM changes, sometimes including multifocal lesions. The present study demonstrates that “pure” DAWM without multifocal lesions exhibits in vivo quantitative MR imaging measures intermediate to and significantly different from those of focal WM lesions and those of NAWM.

These results are in agreement with findings of a recent postmortem MR imaging–histopathology correlation study that used the same quantitative MR imaging measures in fixed brain sections⁴ and that also observed that quantitative MR imaging measures of DAWM showed intermediate values between those of focal WM lesions and those of NAWM. We, therefore, conclude that the applied quantitative MR imaging techniques are useful as paraclinical tools for measuring the severity and evolution of DAWM in patients with MS.

Previous postmortem histopathologic findings evidenced that though quantitative MR imaging measures of DAWM are intermediate to those of NAWM and focal WM lesions, the disease process in DAWM is by no means a stage preceding focal lesions, but a different pathologic phenomenon altogether, involving old chronic gliosis with extensive axonal and myelin loss.⁴ Remyelination or other evidence of resolution of pathology was not observed in that study, but it would certainly be important to scrutinize those findings in independent studies on different samples. Combined with a moderate activation of microglia, these observations are certainly compatible with secondary (wallerian) degeneration, similar to what has been reported in white matter hyperintensities in Alzheimer disease by Gouw et al.²⁷ If DAWM indeed represents secondary axonal degeneration, studying DAWM changes in vivo will be of paramount importance for understanding and monitoring the disease process.

Although groups in this study were relatively small, the results for T1 and MTR suggest that DAWM in PPMS may be different from DAWM in SPMS. This finding is important because it establishes that pathologic changes in DAWM are not the same in all patients with MS and, in fact, may differ significantly between 2 clinical groups. Whether the differences observed between the PPMS and SPMS patients in the present study are strictly the result of a fundamental difference between PPMS and SPMS cannot be concluded from our results. The retrospective nature of the present study implies that we have been unable to influence the size and composition of the patient groups. From the groups of patients with PPMS and SPMS included in the original study, we had to exclude several patients because data were not complete for all 4 measures (MTR, T1, ADC, and FA). Although the 2 resulting patient groups were representative of their respective disease types, they did differ in terms of disease durations and EDSS

scores (though not significantly). Therefore, it cannot be excluded that the observed difference between our groups of patients with PPMS and SPMS is partly or wholly the result of a longer and/or more severe disease process in the patients with SPMS. Lower numbers of inflammatory infiltrates were reported in the WM in PPMS compared with SPMS in a postmortem study.²⁸ It has been hypothesized that PPMS may be more primarily neurodegenerative in nature, compared with the relapse-onset type of disease.²⁹ Further in vivo studies should address the putative DAWM differences between PPMS and SPMS in well-matched groups. The nature and severity of tissue changes in DAWM should also be compared between PPMS and SPMS through postmortem histopathologic studies.

Although in this study, ROI sizes differed somewhat between patient groups and tissue types, this difference is unlikely to have affected the results. Most important, the ROIs were placed in the same anatomic regions, thus controlling for regional variations in the quantitative MR imaging measures, and were of sufficient size to provide good sampling of each tissue type. Because of the small sizes of the lesions present in these regions in many patients, the lesion ROIs were overall smaller than the DAWM ROIs, which can be expected to result in somewhat less accurate determination of the average values of the quantitative MR imaging measures in lesional tissue but would not have any systematic effect on the values themselves or the statistical comparisons performed in this study.

The comparison between clinical groups demonstrates that the severity of tissue damage in DAWM may vary between patients; and as argued by Chen et al,¹ quantitative MR imaging will be a valuable tool for studying DAWM changes comprehensively. The most important next step in this process would be to investigate the clinical correlate of the observed quantitative MR imaging changes in DAWM, by assessing relations with clinical measures, by comparing DAWM across the course of relapse-onset disease, and by measuring changes with time through prospective follow-up studies applying quantitative MR imaging of DAWM regions. Furthermore, whether DAWM severity is related to the abundance of or severity of the damage in the focal WM lesions should be investigated as well as the relations of DAWM with cortical atrophy, to scrutinize the hypothesis that DAWM may consist of secondary axonal degeneration. In the current retrospective study, groups were too small and available image data inadequate to address these issues.

The current study was designed to investigate DAWM, not to compare MR imaging techniques, and the different MR imaging techniques were, therefore, not designed to be as comparable as possible. However, our results suggest that though T1, MTR, ADC, and FA all show the same trends, which are in agreement with postmortem findings, of these 4, T1 and MTR may be especially sensitive to the changes occurring in DAWM. These, therefore, seem the most promising candidates for use in future studies investigating the clinical and imaging correlates of DAWM.

It is likely that previous histogram studies of quantitative MR imaging measures obtained from NAWM have been influenced by changes in DAWM. The present study demonstrates that DAWM exhibits the quantitative MR imaging measures that are more abnormal than those of “real”

NAWM, differing by as much as 30%. While taking care to exclude focal or confluent WM lesions from the analyses, previous histogram studies have most likely included DAWM as defined according to the criteria of Seewann et al,⁴ because DAWM as defined by these criteria exhibits fairly subtle signal-intensity increases. To understand the respective roles of NAWM and DAWM in MS, future studies should also investigate the extent of DAWM in addition to studying its severity with quantitative MR imaging techniques.

In conclusion, the present retrospective study demonstrated that 4 widely used in vivo quantitative MR imaging measures can discriminate “pure” DAWM—without multifocal lesional abnormalities—from both focal WM lesions and NAWM, confirming earlier postmortem results in vivo and laying the foundations for future prospective clinical studies of DAWM. Moreover, the results suggest that DAWM may be more abnormal in patients with SPMS than in patients with PPMS.

Acknowledgments

We thank all patients who participated in this study and Petra J.W. Pouwels, PhD, Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, the Netherlands, for help with quantitative MR imaging techniques.

References

- Chen SC, Chung HW, Liou M. Measurement of volumetric lesion load in multiple sclerosis: moving from normal- to dirty-appearing white matter. *AJNR Am J Neuroradiol* 2003;24:1929–30
- Ge Y, Grossman RI, Babb JS, et al. Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis. *AJNR Am J Neuroradiol* 2003;24:1935–40
- Ropele S, Strasser-Fuchs S, Augustin M, et al. A comparison of magnetization transfer ratio, magnetization transfer rate, and the native relaxation time of water protons related to relapsing-remitting multiple sclerosis. *AJNR Am J Neuroradiol* 2000;21:1885–91
- Seewann A, Vrenken H, van der Valk P, et al. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. *Arch Neurol* 2009;66:601–09
- Moore GR, Laule C, MacKay A, et al. Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss. *J Neurol* 2008;255:1802–11
- Karampekios S, Papanikolaou N, Papadaki E, et al. Quantification of magnetization transfer rate and native T1 relaxation time of the brain: correlation with magnetization transfer ratio measurements in patients with multiple sclerosis. *Neuroradiology* 2005;47:189–96
- Papanikolaou N, Papadaki E, Karampekios S, et al. T2 relaxation time analysis in patients with multiple sclerosis: correlation with magnetization transfer ratio. *Eur Radiol* 2004;14:115–22
- Vrenken H, Pouwels PJ, Geurts JJ, et al. Altered diffusion tensor in multiple

- sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. *J Magn Reson Imaging* 2006;23:628–36
- Vrenken H, Geurts JJ, Knol DL, et al. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. *Radiology* 2006;240:811–20
- Vrenken H, Pouwels PJ, Ropele S, et al. Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. *Mult Scler* 2007;13:708–16
- Bitsch A, Kuhlmann T, Stadelmann C, et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. *Ann Neurol* 2001;49:793–96
- Brex PA, Parker GJ, Leary SM, et al. Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. *J Neurol Neurosurg Psychiatry* 2000;68:627–32
- MacKay AL, Vavasour IM, Rauscher A, et al. MR relaxation in multiple sclerosis. *Neuroimaging Clin N Am* 2009;19:1–26
- van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. *Ann Neurol* 1999;46:747–54
- van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. *Neurology* 1998;50:1282–88
- Vavasour IM, Li DK, Laule C, et al. Multi-parametric MR assessment of T(1) black holes in multiple sclerosis: evidence that myelin loss is not greater in hypointense versus isointense T(1) lesions. *J Neurol* 2007;254:1653–59
- Ropele S, Fazekas F. Magnetization transfer MR imaging in multiple sclerosis. *Neuroimaging Clin N Am* 2009;19:27–36
- Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. *Ann Neurol* 2004;56:407–15
- Schmierer K, Wheeler-Kingshott CA, Tozer DJ, et al. Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. *Magn Reson Med* 2008;59:268–77
- Schmierer K, Wheeler-Kingshott CA, Boulby PA, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. *Neuroimage* 2007;35:467–77
- Venkatesan R, Lin W, Haacke EM. Accurate determination of spin-density and T1 in the presence of RF-field inhomogeneities and flip-angle miscalibration. *Magn Reson Med* 1998;40:592–602
- Nolte UG, Finsterbusch J, Frahm J. Rapid isotropic diffusion mapping without susceptibility artifacts: whole brain studies using diffusion-weighted single-shot STEAM MR imaging. *Magn Reson Med* 2000;44:731–36
- Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. *Med Image Anal* 2001;5:143–56
- Jenkinson M, Bannister P, Brady M, et al. Improved optimization for the robust and accurate linear registration and motion correction of brain images. *Neuroimage* 2002;17:825–41
- Ropele S, Filippi M, Valsasina P, et al. Assessment and correction of B1-induced errors in magnetization transfer ratio measurements. *Magn Reson Med* 2005;53:134–40
- Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. *J Magn Reson B* 1996;111:209–19
- Gouw AA, Seewann A, Vrenken H, et al. Heterogeneity of white matter hyperintensities in Alzheimer’s disease: post-mortem quantitative MRI and neuropathology. *Brain* 2008;131:3286–98
- Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. *Brain* 2005;128:2705–12
- Miller DH, Leary SM. Primary-progressive multiple sclerosis. *Lancet Neurol* 2007;6:903–12